1997 influenza season

1997 influenza season
Season	1997
Known for	Avian influenza incidents, influenza A(H3N2) activity
Major outbreaks	Hong Kong avian influenza cases, Northern Hemisphere winter season
Notable variants	H3N2, H1N1, avian H5N1 (sporadic)
Deaths estimated	variable by region
Vaccine	1997–98 trivalent influenza vaccine

1997 influenza season The 1997 influenza season encompassed seasonal influenza circulation and notable zoonotic events that intersected with international trade, public health, and veterinary sectors; this season coincided with heightened attention to Hong Kong poultry markets, World Health Organization surveillance updates, and regional epidemics across the Northern Hemisphere, prompting coordination among institutions such as the Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and national ministries of health.

Background

The season unfolded against a backdrop of ongoing global surveillance coordinated by the World Health Organization Global Influenza Surveillance Network, with contributions from sentinel sites in United States, United Kingdom, Japan, Australia, and China; these efforts informed vaccine strain selection processes used by advisory bodies like the WHO Influenza Advisory Committee and regional technical groups including the Pan American Health Organization and the European Influenza Surveillance Scheme. Simultaneously, events in Hong Kong involving avian hosts drew attention from veterinary organizations such as the Food and Agriculture Organization and research institutions including the Centers for Disease Control and Prevention Influenza Division and university laboratories at University of Hong Kong and Oxford University.

Virus Strains and Antigenic Characteristics

Circulating human strains during the season were dominated by influenza A subtypes, notably seasonal H3N2 and H1N1, with antigenic drift detected through hemagglutination inhibition assays conducted by reference centers at the CDC Influenza Laboratory, the WHO Collaborating Centre for Reference and Research on Influenza in London, and the National Institute of Infectious Diseases (Japan). Isolates were compared to vaccine reference strains recommended by the WHO and evaluated alongside avian-origin isolates such as the H5 subtype recovered from poultry in Hong Kong; sequence analysis by teams at Imperial College London, University of Hong Kong, and the Scripps Research Institute highlighted amino acid substitutions in hemagglutinin and neuraminidase proteins that altered antigenic sites recognized by panels of sera assembled by institutions including the American Red Cross and the Pasteur Institute.

Epidemiology and Geographic Spread

Seasonal peaks in influenza-like illness were reported across the United States, Canada, United Kingdom, France, Germany, and Japan following typical Northern Hemisphere patterns, with surveillance reports from the CDC Flusurv system, the Health Protection Agency in the UK, and the National Institute of Public Health and the Environment in Netherlands documenting increased outpatient visits, hospital admissions, and laboratory confirmations. Concurrently, zoonotic transmissions associated with poultry in Hong Kong led to case investigations by the Department of Health (Hong Kong) and epidemiologic assessments by the World Health Organization, sparking international communications among agencies such as the Centers for Disease Control and Prevention, the Food and Agriculture Organization, and the World Organisation for Animal Health. Global travel hubs including Hong Kong International Airport, John F. Kennedy International Airport, and Heathrow Airport facilitated surveillance challenges noted by transport ministries and port health authorities in Singapore, Malaysia, and Thailand.

Clinical Impact and Mortality

Clinical presentations ranged from self-limited influenza-like illness to severe pneumonia and acute respiratory distress among high-risk groups including elderly persons, residents of long-term care facilities monitored by agencies like the Centers for Medicare & Medicaid Services, and patients with chronic conditions managed by tertiary hospitals such as Massachusetts General Hospital and Royal Free Hospital. Mortality estimates varied regionally, with excess deaths attributed to seasonal influenza recorded by national statistical offices such as the Office for National Statistics in the United Kingdom and the National Center for Health Statistics in the United States; tertiary care reports and autopsy series from academic centers including Johns Hopkins Hospital and Peking University First Hospital documented complications including secondary bacterial pneumonia caused by pathogens studied at institutes like the Pasteur Institute and Statens Serum Institut.

Public Health Response and Control Measures

Public health responses involved surveillance intensification, case investigation, targeted antiviral use, and poultry market interventions coordinated among the World Health Organization, national ministries of health, and local public health departments such as the New York City Department of Health, the Hong Kong Department of Health, and the Tokyo Metropolitan Government Bureau of Social Welfare and Public Health. In Hong Kong, authorities implemented poultry culling, market rest days, and biosecurity measures informed by veterinary advisors from the Food and Agriculture Organization and the World Organisation for Animal Health, while human health measures included isolation of cases, contact tracing by teams from the CDC and the London School of Hygiene & Tropical Medicine, and guidance on antiviral agents like oseltamivir and amantadine provided through national formularies and clinical practice guidelines from academic societies such as the Infectious Diseases Society of America.

Vaccine Development and Effectiveness

Vaccine strain selection for the 1997–98 trivalent influenza vaccine incorporated antigenic data from WHO Collaborating Centres and national reference laboratories including the CDC Influenza Division and the WHO Collaborating Centre on Influenza in Melbourne, with manufacturing by pharmaceutical companies such as GlaxoSmithKline, Sanofi Pasteur, and AstraZeneca supplying inactivated split-virus formulations to immunization programs administered by ministries of health in Canada, Australia, and Spain. Post-season vaccine effectiveness studies conducted by research groups at CDC, Karolinska Institutet, and McMaster University used case-control and cohort methods to estimate protection against medically attended influenza, noting variable effectiveness linked to antigenic match between vaccine strains and circulating H3N2 and H1N1 viruses, as described in surveillance summaries by the World Health Organization and national public health agencies.

Category:Influenza seasons